JP6938465B2 - カンナビノイドとｎ−アシルエタノールアミンの組み合わせ - Google Patents

カンナビノイドとｎ−アシルエタノールアミンの組み合わせ Download PDF

Info

Publication number
JP6938465B2
JP6938465B2 JP2018507796A JP2018507796A JP6938465B2 JP 6938465 B2 JP6938465 B2 JP 6938465B2 JP 2018507796 A JP2018507796 A JP 2018507796A JP 2018507796 A JP2018507796 A JP 2018507796A JP 6938465 B2 JP6938465 B2 JP 6938465B2
Authority
JP
Japan
Prior art keywords
salt
pharmaceutical composition
acylethanolamine
certain embodiments
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018507796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514589A5 (enExample
JP2018514589A (ja
Inventor
シュムレビッツ アッシャー
シュムレビッツ アッシャー
ハバー エルラン
ハバー エルラン
ブレナー エフライム
ブレナー エフライム
Original Assignee
エスシーアイ スパーク リミティド
エスシーアイ スパーク リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスシーアイ スパーク リミティド, エスシーアイ スパーク リミティド filed Critical エスシーアイ スパーク リミティド
Publication of JP2018514589A publication Critical patent/JP2018514589A/ja
Publication of JP2018514589A5 publication Critical patent/JP2018514589A5/ja
Priority to JP2021057991A priority Critical patent/JP2021107401A/ja
Application granted granted Critical
Publication of JP6938465B2 publication Critical patent/JP6938465B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2018507796A 2015-04-29 2016-04-19 カンナビノイドとｎ−アシルエタノールアミンの組み合わせ Active JP6938465B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021057991A JP2021107401A (ja) 2015-04-29 2021-03-30 カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
US62/154,144 2015-04-29
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021057991A Division JP2021107401A (ja) 2015-04-29 2021-03-30 カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Publications (3)

Publication Number Publication Date
JP2018514589A JP2018514589A (ja) 2018-06-07
JP2018514589A5 JP2018514589A5 (enExample) 2019-05-30
JP6938465B2 true JP6938465B2 (ja) 2021-09-22

Family

ID=57199061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018507796A Active JP6938465B2 (ja) 2015-04-29 2016-04-19 カンナビノイドとｎ−アシルエタノールアミンの組み合わせ
JP2021057991A Pending JP2021107401A (ja) 2015-04-29 2021-03-30 カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021057991A Pending JP2021107401A (ja) 2015-04-29 2021-03-30 カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Country Status (12)

Country Link
US (7) US11234956B2 (enExample)
EP (2) EP4193993A3 (enExample)
JP (2) JP6938465B2 (enExample)
CN (2) CN107530317A (enExample)
AU (3) AU2016254685B2 (enExample)
CA (1) CA2984088C (enExample)
DK (1) DK3288553T3 (enExample)
ES (1) ES2935605T3 (enExample)
IL (2) IL291864A (enExample)
MA (1) MA41997A (enExample)
PL (1) PL3288553T3 (enExample)
WO (1) WO2016174661A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021107401A (ja) * 2015-04-29 2021-07-29 エスシーアイ スパーク リミティド カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210052478A1 (en) * 2018-01-05 2021-02-25 Altus Labs, Llc Personal care compositions
WO2019145783A1 (en) * 2018-01-29 2019-08-01 Therapix Biosciences Ltd. Compositions and methods for treating obstructive sleep apnea
EP3773512A4 (en) * 2018-04-03 2021-12-29 Pure Green, LLC Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
AU2020260090C9 (en) * 2019-04-15 2023-08-31 Metagenics LLC Novel hemp and PEA formulation and its use
CA3134885A1 (en) * 2019-04-23 2020-10-29 SciSparc Ltd. Compositions and methods for potentiating derivatives of 4-aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
US12491200B2 (en) 2019-05-23 2025-12-09 Igc Pharma Ip, Llc Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome
EP4017486A4 (en) * 2019-08-19 2023-09-20 Buzzelet Development And Technologies Ltd COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
US11918688B2 (en) 2021-01-11 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
US20230000936A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2007006319A2 (en) 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PL2796129T3 (pl) * 2009-09-07 2015-11-30 Epitech Group S P A Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
CN107530317A (zh) * 2015-04-29 2018-01-02 希拉匹克斯生物科学有限公司 大麻素类和n‑酰基乙醇胺的组合

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021107401A (ja) * 2015-04-29 2021-07-29 エスシーアイ スパーク リミティド カンナビノイドとｎ−アシルエタノールアミンの組み合わせ

Also Published As

Publication number Publication date
US20180078523A1 (en) 2018-03-22
US11207290B2 (en) 2021-12-28
DK3288553T3 (da) 2023-01-23
US20200038367A1 (en) 2020-02-06
AU2023251426A1 (en) 2023-11-09
IL291864A (en) 2022-06-01
US20200022946A1 (en) 2020-01-23
PL3288553T3 (pl) 2023-03-20
AU2016254685A1 (en) 2017-11-09
CA2984088A1 (en) 2016-11-03
AU2023251426B2 (en) 2025-11-27
AU2021206784B2 (en) 2023-07-20
US20210393577A1 (en) 2021-12-23
EP4193993A2 (en) 2023-06-14
US20200030281A1 (en) 2020-01-30
EP4193993A3 (en) 2023-07-19
US20220071949A1 (en) 2022-03-10
MA41997A (fr) 2021-03-31
EP3288553A1 (en) 2018-03-07
WO2016174661A1 (en) 2016-11-03
EP3288553A4 (en) 2018-12-26
IL255238B (en) 2022-05-01
IL255238A0 (en) 2017-12-31
EP3288553B1 (en) 2022-12-28
CN107530317A (zh) 2018-01-02
US20220071948A1 (en) 2022-03-10
US11234956B2 (en) 2022-02-01
US11197845B2 (en) 2021-12-14
CN116549437A (zh) 2023-08-08
JP2021107401A (ja) 2021-07-29
JP2018514589A (ja) 2018-06-07
AU2021206784A1 (en) 2021-08-12
CA2984088C (en) 2024-04-09
AU2016254685B2 (en) 2021-04-22
ES2935605T3 (es) 2023-03-08

Similar Documents

Publication Publication Date Title
JP6938465B2 (ja) カンナビノイドとｎ−アシルエタノールアミンの組み合わせ
US20170360798A1 (en) Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
AU2002311784B8 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20210299119A1 (en) Methods Of Providing Weight Loss Therapy In Patients With Major Depression
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
HK40085288A (en) Combinations of cannabinoids and n-acylethanolamines
AU2012276476B2 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
TWI735658B (zh) 用於減少代謝症候群之組合物及其應用
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210330

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210330

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210623

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210901

R150 Certificate of patent or registration of utility model

Ref document number: 6938465

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250